Gilead Sciences and Arcus Biosciences Announce Positive Phase 2 ARC-7 Trial Results Demonstrating Improved Progression-Free Survival in First-Line NSCLC with PD-L1 High Expression

Intelligent Finance APP learned that today, Gilead Sciences (GILD.US) and Arcus Biosciences (RCUS.US) announced the latest interim analysis results of the Phase 2 clinical trial ARC-7 for patients with metastatic non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The results showed that in patients with high PD-L1 expression in tumors, compared with anti-PD-1 antibody monotherapy, the combination of anti-TIGIT antibody and anti-PD-1 antibody as first-line therapy significantly improved the objective response rate (ORR) and extended progression-free survival (PFS).

It is reported that the ARC-7 study is a randomized, open-label Phase 2 clinical trial designed to compare and evaluate the efficacy of three treatment regimens in patients with non-small cell lung cancer: a dual therapy consisting of the anti-TIGIT antibody (domvanalimab) and the anti-PD-1 antibody (zimberelimab), a triple therapy comprising the anti-TIGIT antibody (domvanalimab), the anti-PD-1 antibody (zimberelimab), and the adenosine A2a/b receptor antagonist (etrumadenant), and a monotherapy regimen of zimberelimab alone.